Axsome Therapeutics Inc (AXSM)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

200 BROADWAY, 3RD FLOOR NEW YORK, NY 10038

Axsome Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The Company focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. Axsome Therapeutics serves patients worldwide.

Data based on most recent fiscal year report
Market Cap54.718 Million Shares Outstanding25.45 Million Avg Volume362.297 Thousand
1-Yr BETA vs S&P TR1.414 Current Ratio2.9 Quick Ratio2.9
View SEC Filings from AXSM instead.
Q2 2019 All Institutions Hedge Funds 1
To trade AXSM now:
Filers who had this stock in their top 10: 6 3 (0.31%)
13F Filers holding this stock: 104 22 (2.27%)
Aggregate 13F shares on 06/30/2019: 18.244 Million 7.915 Million
Aggregate 13F shares on 03/31/2019: 14.727 Million 8.159 Million
Percent change: 23.88% -3.00%
Funds creating new positions: 52 9
Funds Adding to an existing position: 25 6
Funds closing out their position: 13 3
Funds reducing their position: 20 6
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AXSM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

2.2 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PIZZIE NICK CHIEF FINANCIAL OFFICER

  • Officer
40,500 2019-09-26 4

MAREK DAVID C CHIEF COMMERCIAL OFFICER

  • Officer
0 2019-09-04 2

POTTER MYRTLE S

  • Director
0 2019-08-23 1

JEFFS ROGER

  • Director
103,532 2019-07-03 3

COLEMAN MARK

  • Director
673,948 2019-06-25 5

SAAD MARK E

  • Director
0 2019-06-07 3

TABUTEAU HERRIOT CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
  • 10% Owner
0 2019-03-19 1

GOLUBIESKI JOHN CHIEF FINANCIAL OFFICER

  • Officer
0 2017-08-04 0

AMES CONSTANCE VICE PRESIDENT, FINANCE

  • Officer
0 2017-03-15 0

KAYE RANDALL CHIEF MEDICAL OFFICER

  • Officer
6,022 2015-12-23 0

ANTECIP CAPITAL LLC

  • 10% Owner
7,344,500 2015-11-19 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

PIZZIE NICK - Officer CHIEF FINANCIAL OFFICER

2019-09-26 P 2,180 $24.80 a 40,440 40,500.00 direct

MAREK DAVID C - Officer CHIEF COMMERCIAL OFFICER

2019-09-04 A 125,000 a 125,000 0.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments